Study details
Enrolling now
A Phase II Trial of Loncastuximab Tesirine for Relapsed/Refractory Large B-cell Lymphoma After CAR T-cell Therapy
M.D. Anderson Cancer Center
NCT IDNCT05464719ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 3.4 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing if loncastuximab tesirine (lonca) can help control large B-cell lymphoma that has returned after CAR T-cell therapy. The safety of this treatment will also be studied.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Loncastuximab Tesirine
PhasePhase 2
DrugLoncastuximab Tesirine
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
loncastuximab tesirine
Body systems
Oncology